News & Updates
Filter by Specialty:
Nadofaragene firadenovec promotes bladder preservation in BCG-unresponsive NMIBC
Nadofaragene firadenovec-vncg helps preserve the bladder in patients with bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle-invasive bladder cancer (NMIBC) at 5 years, with an acceptable safety profile, as shown in a phase III trial.
Nadofaragene firadenovec promotes bladder preservation in BCG-unresponsive NMIBC
05 Jul 2024
9-month, oral modified treatment regimens make the grade in drug-resistant TB
Nine-month, fully oral modified short treatment regimens (mSTRs) consisting of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine or delamanid appear to yield high treatment success and good safety results in the treatment of patients with rifampicin-resistant, fluoroquinolone-susceptible tuberculosis (TB), according to a study.
9-month, oral modified treatment regimens make the grade in drug-resistant TB
04 Jul 2024
Low-intensity shockwave therapy plus tadalafil improves erectile function in men with ED
Combination treatment with 12 sessions of low-intensity shockwave therapy (LiST) three times weekly and daily tadalafil for 4 weeks results in a 2-point difference in the International Index of Erectile Function–Erectile Function domain (IIEF-EF) compared with sham therapy plus tadalafil in patients with severe vasculogenic erectile dysfunction (ED) after 1 and 3 months of treatment completion.
Low-intensity shockwave therapy plus tadalafil improves erectile function in men with ED
04 Jul 2024
NOTUS boosts dupilumab role for COPD, type 2 inflammation
The phase III NOTUS trial further validates the potential of the monoclonal antibody dupilumab in reducing exacerbations and improving lung function and quality of life (QoL) in patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation.
